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Tuberculosis (TB)  remains the main infectious cause of deaths in the world. Due to the slow
metabolism of the causative agent, Mycobacterium tuberculosis, the isolation, identification
and drug susceptibility testing requires several weeks. New techniques have improved specificity,
turnaround time and cost effectiveness. Although these methods yield results within hours from
sample collection, the clinical significance of each positive result requires rigorous evaluation
in most cases. Herein the advantages and disadvantages of the most promising molecular
techniques for detection of TB and drug resistance are discussed.
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Avances recientes en métodos moleculares para el diagnóstico precoz y tuberculosis
resistente al tratamiento
La tuberculosis sigue siendo la principal causa de mortalidad por un agente infeccioso a
escala mundial. Debido al metabolismo lento de su agente etiológico, Mycobacterium
tuberculosis, el aislamiento, la identificación y las pruebas de susceptibilidad tardan varias
semanas. Nuevas técnicas moleculares desarrolladas ofrecen mejorías en la especificidad, el
tiempo para la obtención de resultados y su costo-efectividad. Estas pruebas producen
resultados en pocas horas a partir de la toma de muestra, pero su relevancia clínica requiere
aún ser evaluada rigurosamente en la mayoría de los casos. En esta revisión se discuten las
ventajas y las desventajas de las pruebas moleculares más promisorias desarrolladas para el
diagnóstico de la tuberculosis y la tuberculosis resistente a medicamentos.
Palabras clave: tuberculosis, diagnóstico, resistencia a fármacos, micobacteriófagos, PCR,
E-MTD.
REVIEW ARTICLE
Tuberculosis (TB) remains the world’s leading
infectious cause of death in adults. The death toll
is worsened by the emergence of drug resistant
Mycobacterium tuberculosis, the causative agent
of TB (1). The first report on drug resistance TB
was described shortly after the introduction of anti-
TB chemotherapy (2). Only a year later the
phenomenon of antibiotic resistance was clearly
illustrated when the British Medical Research
Council showed that mortality in TB cases was
similar in patients treated or untreated with
streptomycin. Such observation led to the
conclusion that TB should be treated with a regimen
composed of more than one antibiotic (4). The
emergence of multi-drug resistant (MDR) strains
was observed during the subsequent decades with
little attention by health authorities. During the
1990s major MDR-TB outbreaks were reported in
the USA, Russia, and other countries. In New York
City in 1991, 19.0% of all prevalent clinical isolates
were MDR [by convention, MDR isolates are
resistant at least to isoniazid (INH) and rifampicin
(RIF)] (5-7). Since then, drug resistance (DR) TB
has been reported in almost all geographical
settings, underscoring the impor tance of
expanding and strengthening TB control efforts
worldwide (1,5,8,9).
It is clear that efficient diagnosis of TB and DR
are important factors to improve the TB control
program. Early diagnosis can lead to smaller
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number of contacts per case and lower MDR rates,
for which the molecular methods used either for
detection of M. tuberculosis or diagnosis of DR
have an advantage of yielding results in only
hours, while conventional microbiological
approaches require days to weeks. Some
techniques have simple setup and analysis
permitting their applications in clinical settings. In
this review some of the most important or
promising molecular techniques will be discussed.
Detection of Mycobacterium tuberculosis
Molecular techniques determine the presence of
M. tuberculosis in clinical specimens by detecting
specific nucleic acid sequences after being
amplified. The Food and Drug Administration (FDA)
has approved only two molecular techniques for
direct detection of M. tuberculosis from clinical
specimens, the Amplicor M. tuberculosis test
(Amplicor; Roche Diagnostic Systems, Inc.,
Branchburg, NJ) and the Enhanced M. tuberculosis
Direct Test (E-MTD; Gen- Probe, San Diego, CA).
Amplicor test
This technique detects the presence of the
mycobacterial 16S ribosomal RNA (rRNA) gene
by PCR amplification followed by an ELISA
reaction. The clinical specimen is processed with
the standard N-acetyl-L-cysteine-NaOH
decontamination method, followed by amplification
of the mycobacterial 16S rRNA gene. The
presence of the biotin-labeled amplicon is done
by an ELISA reaction, for which the PCR product
is denatured and added to a microtiter plate in
which there is an immobilized DNA probe specific
to the target. Presence of the target-probe hybrid
is revealed by addition of an avidin-horseradish
peroxidase conjugate antibody, and revealed by
addition of peroxide and 3,3’,5,5’-tetramethyl-
benzidine in dimethylformamide to form a color
complex. The results are measured with a
photometer. False-positive results produced by
carryover contamination are prevented by the
incorporation of dUTP coupled with uracil-N-
glycosylase restriction. The complete process
takes about 6.5 hours, and an automated version
of the test called Cobas Amplicor is available.
Several studies have evaluated the Amplicor test
efficiency in clinical settings. It performed well
among acid-fast bacilli (AFB) smear-positive
patients with a specificity of 99.0% and sensitivity
between 80.0-92.0%, while it presents lower
sensitivity values (40.0-73.0%) among smear
negative patients (10-14).  Moreover, FDA
approved Amplicor only for AFB smear-positive
respiratory specimens. The studies agree that the
specificity of the culture is similar to Amplicor test
in detecting M. tuberculosis in respiratory samples
when using bacterial, histopathological, and clinical
data as gold standards, but the sensitivity is
reported either as similar to culture (~100.0%)
(15,16) or lower (42-73%) (17).
E-MTD
The assay is based on the transcription mediated
amplification system (TMA) developed by Kwoh
et al. (18), which is described in figure 1. The
mycobacterial rRNA from the target cells is
released by sonication and amplified a billion fold
by TMA. The reactions take place at a constant
temperature, replacing the thermal cycles of a
PCR. The RNA amplicon produced is detected in
solution with an acridinium ester-labeled DNA
probe, using a luminometer. The assay takes 3.5
hours to yield results after the clinical specimen
is processed with the standard N-acetyl-L-
cysteine-NaOH decontamination method.
E-MTD has FDA approval only for respiratory
specimens, either AFB-positive or -negative. A
comparison between E-MTD and Amplicor showed
similar performance in detecting M. tuberculosis.
However, Amplicor can be fully automated and
has internal controls to detect PCR inhibitions,
while E-MTD does not (19). The equipment
availability in the reference laboratory might play
a role in choosing either technique: Amplicor
requires a thermocycler and a photometer (or the
Cobas Amplicor apparatus) while E-MTD requires
a heat block and a photometer.
The Centers for Disease Control and Prevention
(CDC) designed general guidelines for the clinical
applications of nucleic acid amplification assays
for TB diagnosis  (20). They recommend collecting
sputum specimens on 3 different days for AFB
smear and culture. The nucleic acid detection tests
should be performed on the first sample, the first
smear positive specimen, and additional
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specimens if needed. According to the results
obtained, there are 4 different scenarios: 1) if smear
and amplification are positive, the patient is
presumed to have TB; 2) in cases where smear is
positive and nucleic acid amplification tests are
negative, a test for amplification reactions
inhibitors must be performed; in case inhibitors
are detected, these assays are omitted; when there
are no inhibitors and the smear is positive, the
patient is presumably infected with non-
tuberculous mycobacteria; 3) if the smear is AFB-
negative with positive amplification, the second
specimen is evaluated, and if similar results are
observed the patient is presumed to have TB; 4)
in cases where all sputum specimens are both
smear and amplification negative, the patient can
be presumed to be non-infectious, but in this case
the possibility of active TB cannot be ruled out
and the physician must evaluate the possibility of
TB therapy (20,21).
Clinical evaluation of extrapulmonary TB is often
uncertain and nucleic acid amplification techniques
offer a new alternative to clinicians for accurate
diagnosis of TB. Several studies report similar
performance of Amplicor and E-MTD tests using
extrapulmonary samples when using culture as
gold standard (22,23) but there are reports in which
performance is questioned (14). It is clear that
further clinical evaluation is required before FDA
approves these techniques for non-respiratory
specimens, and caution must be practiced by
physicians in these cases.
There are numerous in-house PCR-based
techniques developed for the detection of TB in
diverse clinical specimens with promising results
(24-29). Such assays offer a TB diagnostic
alternative in children with high agreement with
standard techniques (30-32). On the other hand,
some PCR assays can yield false negative results
(33-35), underscoring the importance of further
evaluation and validation of each assay.
Identification of antibiotic
resistance-associated mutations
M. tuberculosis acquires drug resistance by
antibiotic selection of mutations that occur
randomly at chromosomal loci. No plasmids or
transposable elements are involved in this
process. Nucleotide changes (point mutations,
small deletions or insertions) confer resistance to
single drugs, and the stepwise accumulation of
these mutations leads to MDR-TB. Drug-resistant
strains emerge when chemotherapy is intermittent
or otherwise inadequate, underscoring the
importance of an early detection of DR. The
increase in drug resistant TB and the limited
number of therapeutic agents is renewing the effort
in the study of the molecular mechanisms of
resistance. Before discussing the methods
designed to detect these mutations, a brief
description of the molecular mechanisms of DR
in M. tuberculosis will be made [for reviews, see
references (36-38)].
RIF is a semisynthetic derivative of rifamycin that
is used as a first-line TB drug. RIF binds to the β
subunit of RNA polymerase, encoded by the rpoB
gene, and inhibits transcription initiation. About
96% of RIF-resistant (RIFR) isolates have point
mutations in an 81-bp region of this gene, the rpoB
core region, and these mutations are absent in
susceptible isolates, making it an ideal target for
development of molecular drug susceptibility
testing methods (39,40). In contrast to RIF, the
genetic basis of resistance to other TB drugs is
more complex. INH is a synthetic, bactericidal
agent that is used only for treatment of TB because
basically all other bacteria are inherently resistant
to INH. Alterations in a relatively large number of
genes have been associated with INH resistance,
but mutations in two genes, katG and inhA, are
found in 75-85% of INH-resistant M. tuberculosis
isolates. Streptomycin is an aminoglycoside
antibiotic that inhibits protein synthesis.
Approximately 65-75% of streptomycin-resistant
M. tuberculosis isolates have mutations in the 16S
rRNA gene or the rpsL gene, which codes for the
ribosomal protein S12. More than 70% of the
pyrazinamide-resistant M. tuberculosis isolates
have mutations in the pncA gene, which encodes
for pyrazinamidase, an enzyme that converts
pyrazinamide to its active form. Ethambutol
inhibits the incorporation of essential mycolic acids
into the mycobacterial cell wall. Mutations in the
embB gene are associated with ethambutol
resistance in ~70% of resistant isolates (36-38).
The presence or absence of mutations in DR-
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associated genes does not necessarily indicate
susceptibility or resistance to the corresponding
antibiotic. Reports of resistant isolates without
mutations in DR-associated genes and reports of
susceptible isolates with mutations in DR-
associated genes indicate a partial understanding
of resistance mechanisms (38,41). Several
mutations have been stated as 'real' resistance-
mutations (i.e. position 315 in katG) (36-38,42),
while some have been stated as 'non-resistant
mutations' [i.e. position 463 in katG (38, 43), and
positions 269 and 312 of kasA (41,43,44)]. In
contrast, the majority of mutations detected come
from studies using samples with low statistical
significance and their DR-association is based
only on the resistant phenotype of the isolate. This
underscores the importance of determining the role
of each 'DR-associated' mutation reported. Cases
where 'real' mutations associated with resistance
are detected are clinically relevant, however their
absence does not necessarily mean that the
organism is susceptible to the drug in question.
For this reason the currently available molecular
methods may aid in rapid detection of such
mutations, but the results must always be
confirmed by phenotypic methods. Some of the
most important techniques for detection of DR-
associated mutations are described below.
DNA sequencing
Sequencing is the most accurate and reliable
method for mutation detection, and it is used as
the gold standard technique. It allows detecting
both previously recognized and unrecognized
mutations. Except for RIF, DNA sequencing is
unlikely to be used in routine detection of DR
mutations because it requires several sequencing
reactions per isolate becoming labor-intensive and
costly.
The Line Probe assay (LiPA)
LiPA (Inno-Genetics N.V., Zwijndrecht, Belgium)
is used to identify M. tuberculosis species and
the presence of mutations in the rpoB core region.
This region is amplified and biotin-labeled by PCR.
This amplicor is detected after hybridization with
a strip in which five probes for wild-type rpoB
sequences, four probes for specific rpoB
mutations, a conjugate control, and M.
tuberculosis control probes were immobilized.
Bound amplicons are then detected with a color
reaction. Banding pattern interpretation allows M.
tuberculosis complex identification and detection
of rpoB mutations. The assay is designed to
specifically detect 4 of the most common rpoB
mutations [~75% of RIFR clinical isolates carry 1
of the 4 mutations (38)] as well as different
mutations in the core region. The test can be
performed on cultures or directly from clinical
specimens in less than 48 hours. Overall
concordance of the LiPA test with phenotypic
susceptibility testing and direct sequencing, when
performed from cultures, varies from 92.2% to
Figure 1. Amplification of the rRNA target from M.
tuberculosis by TMA. 1: Promoter-primer binds to rRNA
target. 2: Reverse transcriptase (RT) creates DNA copy of
rRNA target. 3: RNA:DNA duplex. 4: RNAse H activities of
RT degrades the rRNA. 5: Primer 2 binds to the DNA and
RT creates a new DNA copy. 6: Double-stranded DNA
template with a promoter sequence. 7: RNA polymerase
(RNA Pol) initiates transcription of RNA from DNA template.
8: 100-1000 copies of RNA amplicon are produced. 9: Primer
2 binds to each RNA amplicon and RT creates a DNA copy.
10: RNA:DNA duplex. 11: RNAse H activities of RT
degrades the rRNA. 12: Promoter-primer binds to the newly
synthesized DNA. RT creates a double-stranded DNA and
the autocatalytic cycle repeats resulting in a billion-fold am-
plification. Detection of the RNA amplicon is performed in
an independent reaction. Reproduced with permission of
Dr. Craig S. Hill, Gen-Probe Inc., CA.
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99.0% (46-48), making the LiPA test a useful
method for rapid detection of RIFR.  In cases where
a mixed population of wild type/mutant is present,
LiPA assay is able to detect the presence of the
mutants only when mutants are at least 20% of
the total population (49).
DNA microarrays
DNA microarrays are based on the principle of
hybridization. They allow analysis of large amounts
of DNA sequences with a single hybridization step.
PCR amplicons labeled with fluorophore moieties
are generated from the sample to be hybridized to
a large collection of probes bound to a solid
surface. The bound amplicons emit a fluorescent
signal that is scanned with an epifluorescent
microscope. Probes are designed to hybridize to
fully complementary amplicons. Wild type and
mutant probes are included in the array to
determine the presence of specific mutations.
Microarrays have been used mainly for species
identification and for detection of mutations
associated with RIFR, with excellent concordance
with sequencing results (50,51). New arrays are
being developed covering several mutations in
katG, inhA, rpoB, rpsL and gyrA proving that this
approach has a strong potential for the screening
of DR-associated mutations in M. tuberculosis
(50). The widespread application of microarrays is
limited because they are still under a research
and development stage, require expertise and
sophisticated equipment and are costly.
Molecular beacons
Molecular beacons are hairpin-shaped probes able
to detect the presence of specific nucleic acids
(figure 2). They are designed in such a way that
the loop portion of the molecule is a probe
sequence complementary to a target nucleic acid
molecule. The stem is formed by the annealing of
complementary arm sequences on the ends of
the probe sequence. A quenching moiety is
attached to the end of one arm and a fluorescent
moiety is attached to the end of the other arm.
The stem keeps these two moieties in close
proximity to each other, causing the fluorescence
of the fluorophore to be quenched by energy
transfer. When the probe encounters a target
molecule, it forms a hybrid that is longer and more
stable than the stem hybrid and its rigidity and
length preclude the simultaneous existence of the
stem hybrid. Thus, the molecular beacon
undergoes a spontaneous conformational
reorganization that forces the stem apart, and
causes the fluorophore and the quencher to move
away from each other, leading to the restoration
of fluorescence that can be detected. This is
monitored in real-time, where the fluorescence
increases every cycle in proportion to the
amplification of the hybridizing target, which is not
detected in cases when the target is not
complementary to the beacon (52).  Beacons are
highly sensitive and specific: a single mismatch
in the target sequence diminishes the beacon-
target hybrid stability, allowing the detection of
point mutations. Beacon assays are performed in
sealed wells preventing amplicon contamination,
they are easily implemented, automated and can
be used in high throughput analysis. In the case
Figure 2. Molecular beacon assay. A molecular beacon
has a loop portion complementary to a target nucleic acid
molecule and a stem composed of 2 complementary tails,
one with a quenching moiety (Q) and the other with a
fluorescent moiety (F). A. When closed, fluorophore
fluorescence is quenched by the quencher. B. When the
probe encounters a target molecule, the beacon opens
and hybridizes to it allowing fluorescence to be detected. C.
In the event that the target has a mismatch (shown by a
green box), the stability of the target-beacon is diminished
and beacon remains closed in a non-fluorescent state. In
case the PCR amplicon is complementary to the beacon,
its amplification can be monitored by increase in
fluorescence by real time PCR (D), otherwise no signal
increase is observed (E).
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of RIF, a set of 5 beacons has been designed to
cover the rpoB core region in a single reaction,
with excellent results (53). The assay is sensitive
enough to detect 2 bacilli, offers results in 3 hours
from sputum collection, and identifies the M.
tuberculosis species proving its strong potential
in clinical settings. A different set of molecular
beacons has been designed to screen for
mutations in the regions with higher frequency of
mutations associated with DR for INH [katG
(position 315), the promoter region of inhA, the
oxyR-ahpC intergenic region and positions 66,
269, 312 and 413 of kasA] (54). Results indicate
that the assay is highly specific, but further
research is required to identify the full set of
mutations responsible for INHR.
Single-strand conformation polymorphism
(SSCP)
This technique determines the presence of
mutations in specific DNA regions by their
migration patterns in polyacrylamide gels. The
target region of a gene is amplified by PCR and
the product is denatured into two single-stranded
molecules and subjected to nondenaturing
polyacrylamide gel electrophoresis. Under non-
denaturing conditions, the single-stranded DNA
(ssDNA) molecule has a secondary structure
determined by the nucleotide sequence, buffer
conditions, and temperature. Mutant ssDNAs
migrate to different positions than the wild type
control. SSCP has been used to detect point
mutations in rpoB, with promising results (40,55).
However, there are reports of the presence of silent
mutations (mutations that do not change the
amino-acid sequence) in this region not resulting
in RIFR leading to false positives by SSCP (56).
This technique has risk of amplicon contamination
due to the extensive post-PCR manipulation
required. This technique is not practical for other
antibiotics because they require screening larger
DNA regions and more than one region per
antibiotic.
FRET probes
Fluorescence resonance energy transfer (FRET)
probes, also known as light cycler probes, are
highly specific probes able to detect the presence
of mutations in real time PCR reactions (57,58).
The detection system of light cycler probes is
based on FRET with two different specific
oligonucleotides (figure 3). Hybridization probe 1
is labeled with fluorescein, and hybridization probe
2 is labeled with the fluorophore Light Cycler Red
640. Both probes can hybridize in a head-to-tail
arrangement, bringing the two fluorescent dyes
into close proximity. A transfer of energy between
the two probes results in emission of red
fluorescent light. The level of fluorescence is
proportional to the amount of DNA generated during
the PCR process. In case the template is mutant,
the probe-target stability will decrease and the
probe will remain in solution hindering FRET,
resulting in a flat signal. FRET probe assays for
the rapid detection of INHR and RIFR were
developed and tested with clinical isolates. The
technique yields concordant results with
sequencing data in less than 2 hours (57,58). This
technique has the advantage that the region
covered is larger than the region screened by
molecular beacons, but because it entails the use
of two fluorophore-labeled probes, the cost is
doubled.
Other PCR-based techniques
Numerous in-house PCR approaches have been
developed to detect the presence of specific point
Figure 3. FRET probe assay. A. During the annealing step
of a PCR reaction, target sequence hybridizes to probes 1
and 2 as shown in the figure. Probe 1 is labeled with
fluorescein (FAM) and probe 2 with Light Cycler Red 640
fluorophore (LC red). Upon excitation of fluorescein by a
light beam, the energy released is transferred to LC red by
FRET and red fluorescent light is emitted. Red fluorescence
increases proportionally to the amplification of the target
DNA. B. Mutation presence (blue square) hinders probe
hybridization, and no red fluorescence increase will be
observed (similar effect will be observed when mutation is
located in the region covered by probe 1).
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Figure 4. Simplified scheme for BMI: target sequences are amplified by PCR using a single forward primer and two tailed
reverse primers (each tail with different sequences, A and B). Per assay two PCR amplifications are done: the sample is
amplified using digoxigenin (D) labeled primer (1) and a reaction using a reference DNA, in which the forward primer is
labeled with biotin (B) (2). The case in which the sample has a mutation is shown (3), where an orange circle indicates
the mutation. PCR products of the sample and reference DNA are combined followed by denaturation and re-annealing,
producing partial duplexes that assemble into four-stranded cruciform structures. These structures resolved into fully
hybridized complexes when the strands have a pair of identical opposite arms (4). However, in the case the sample has
a mismatch due to the presence of a mutation, the resolution of the structure is inhibited (5). Detection of the cruciform
structure is achieved by a standard ELISA reaction by means of an immobilized anti-biotin monoclonal antibody and a free
anti-digoxigenin monoclonal antibody (6). After washing, the ELISA reaction is developed and no signal will be observed
in case of a wild type (7), or positive if mutant (8).
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mutations associated to DR. Most of these
techniques have promising results but have not
yet been tested with statistically significant number
of samples.
Several promising assays are based upon the
amplification refractory mutation system (ARMS)
principle. The 3’-end of a wild type PCR primer is
located at the mutation site. In the case of a wild
type template, the DNA polymerase will amplify
the DNA efficiently, yielding a clear band using
gel electrophoresis. In the case of a mutant
Figure 5. Detection of M. tuberculosis by PhaB assay. A. Phages are added to the decontaminated clinical sample. Phages
will infect viable mycobacterial cells present in the solution. B. Ferrous ammonium sulphate is added (viricidal solution) to
destroy all non-infecting phages. C. Phages begin to replicate leading to cell lysis and release of the new phage particles
into the medium (D). E. This solution is added onto a lawn of sensor cells (M. smegmatis) to produce plaques (F). In case
the sample was negative, no plaques will be present (G).
template, the 3’-end of the primer will not hybridize
and the DNA polymerase will not amplify resulting
in the absence of a band by gel electrophoresis.
However, in practice when there is a 3’-end
mismatch a less efficient amplification can be
observed, leading to background that can hinder
the assay interpretation. This background could
be further diminished by a stringent standardi-
zation of the PCR conditions. ARMS has been
applied to different mutations in rpoB, katG and
embB with promising results (59-62). These
approaches offer an inexpensive alternative for
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strain genotyping but their standardization is
laborious with the inherent risk of amplicon
contamination.
Branch Migration Inhibition (BMI) is a novel
technique based on the fact that spontaneous
strand exchange is inhibited by any sequence
difference between two DNA molecules. It offers
a simple approach to detecting all possible
polymorphisms in an amplicon in a single reaction.
A simplified description of the technique is shown
in figure 4. For a detailed description of this
technique please refer to references (63,64). In
this technique two PCR reactions are performed
using in one a reference DNA and in the second
the sample DNA, using the same forward primer
either labeled with digoxigenin or biotin
respectively. In both reactions the reverse primer
used has two different 5’-end tails. The PCR
products are mixed, denatured and re-annealed.
If the sequence is wild type a transient cruciform
structure is resolved into two fully complementary
primer pairs. If the sample has a mutation, the
cruciform structure is more stable and can be
easily detected in an ELISA reaction because it
carries both labels. This technique allows
screening larger regions of DNA in a single reaction
Figure 6. LRP assay principle. LRPs act as molecular vectors of the fflux gene (which codes for the firefly luciferase) into
mycobacterial cells. LRPs are able to inject the viral chromosome specifically into mycobacterial cells. Subsequent fflux
expression depends on the cellular machinery and luciferase activity depends on the availability of cellular ATP and the
addition of luciferin (which is the luciferase substrate) to the medium. Luciferase catalyzes a reaction in which photons
are released to be detected by a photographic film or a luminometer. Emission of light in a sample infected with LRPs and
supplemented with luciferin indicates the presence of viable mycobacterial cells. If the sample is pretreated with antibiotics,
light is detected only if resistant cells are present.
when compared with molecular beacons or FRET
probes. BMI was used for detection of DR to RIF
and pyrazinamide in MTB. Preliminary results are
in agreement with sequencing results, but not with
phenotypic analysis due to the detection of silent
mutations in rpoB (65).
Diagnosis of TB and drug resistance
with mycobacteriophages
Usage of mycobacteriophages for diagnosis of TB
and DR offer a phenotype-based result in short
time and low cost. This is especially important for
diagnosis of DR, because results are obtained
regardless of the mechanisms of DR, mutation
site, with similar turnaround time of molecular
approaches. Molecular techniques determine
presence of specific nucleic acids, either from live
or dead cells, while phages depend only on viable
mycobacterial cells. There are two kinds of
mycobacteriophage-based assays: the phage-
amplified biological assay (phaB) and the
luciferase reporter phages (LRPs).
PhaB
The phaB determines the protection and
amplification of a phage by mycobacteria in clinical
specimens (66,67) (figure 5). The clinical sample
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suspected of containing viable mycobacterial cells
is infected with the phages. Once the infection
has occurred, the cells are washed with a viricidal
solution destroying all extracellular phages. The
intracellular phages will replicate, lysing M.
tuberculosis cells, and new phage particles will
be released into the media. The number of particles
will be proportional to the number of cells infected,
which will be quantified by counting plaques using
a layer of M. smegmatis. If sample aliquots are
treated with antibiotics prior to infection with the
phage, plaques will appear only if the
mycobacterial cells are resistant (66-68).
For the detection of M. tuberculosis a commercial
system has been developed, the FASTplaqueTB
assay (Biotec Laboratories, South Africa) with
promising results using sputum and urine samples,
offering a viable diagnostic alternative for low-
income countries, with a turnaround time of 1 day
from sample collection (69). For the diagnosis of
DR, phaB results have been satisfactory using
Figure 7. Bronx box. A. Picture of the Bronx box. MTB cultures after incubation with and without antibiotics are placed in
microtiter plates. After 8 hours of LRP infection, a buffer with luciferin is added, the plate is sealed with a self-adhesive
transparent acetate film and loaded into the Bronx box. Immediately after the film cassette is loaded over the plate, the door
is closed and the overnight film exposure begins. B. Photographic detection of light emitted by susceptible MTB isolate (1) and
the resistant isolates (2 and 3) incubated during 72 hours in media supplemented with INH, RIF, streptomycin (STR) and
ethambutol (EMB) at the concentrations shown (µg/ml). Wells labeled as control correspond to no antibiotic treatments.
Absence of signal indicates susceptibility. Results shows that isolate 1 is susceptible, isolate 2 is INH and RIFR and isolate 3
is resistant to all antibiotics except ethambutol.
clinical isolates and sputum specimens
(66,67,70,71).
LRPs
LRPs are phages harboring the fflux (firefly
luciferase) gene, which produces visible light when
expressed in the presence of luciferin (enzyme
substrate) and cellular ATP (figure 5). LRPs are
able to infect, replicate and express their genome
(including the fflux gene) within viable
mycobacterial cells. If an LRP-infected clinical
sample releases light after addition of luciferin,
the presence of viable M. tuberculosis is detected
(72). If the sample is incubated with antibiotics
followed by LRP infection, light emission is
proportional to the resistance level (73-75). LRP
assays can be used as well for the identification
of species from the M. tuberculosis complex
(72,76). Luciferase activity can be monitored with
a luminometer or with photographic film. The
luminometer offers higher sensitivity, quantitative
results within 54 hours, simple procedure and
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analysis, and has shown promising results with
clinical isolates and sputum samples (76,77).
Photographic detection is achieved by using the
'Bronx box' (figure 7). The Bronx box is an
inexpensive light-tight box with a Polaroid cassette
that carries a photographic film that is able to
detect light emitted by the infection carried out in
microtiter plates. The Bronx box yields qualitative
results in 94 hours (78). Both techniques have
shown promising results showing high agreement
with BACTEC, MGIT and agar proportion method
as reference (76-78).
Conclusions
The expectation that molecular techniques would
surpass conventional methods for diagnosis of TB
or phenotypic susceptibility testing has not (yet)
been realized. The genetic basis of resistance
must be understood before achieving such a goal.
However, the clinician now has a variety of new
tools to improve the diagnosis of TB and DR. Most
of them still require detailed and systematic
evaluations using standard techniques as
references before their widespread application in
clinical settings. Most of these techniques require
trained personnel and specialized equipment,
hindering their application in field conditions, but
they can be used in reference laboratories as part
of the TB control programs. The physician must
be cautious when using results obtained by these
techniques, especially when diagnosing DR.
Although it is not recommended, these molecular
methods might be used as a complement to the
standard methods in situation of difficult diagnosis,
but never should be used solely to base such
decisions.
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